Skip to content

Understanding (Poly)Phenol Metabolism in People With an Ileostomy

Investigation of in Vivo Endogenous and/or Exogenous Production of Phenolic Metabolites in People With an Ileostomy Using an Oral (Poly)Phenol Challenge Test

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07772362
Acronym
EndOPCT-ileo
Enrollment
20
Registered
2026-08-19
Start date
2026-08-01
Completion date
2028-05-01
Last updated
2026-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ileostomy - Stoma

Keywords

Ileostomy, (Poly)phenol, Bioavailability, Metabolism, Low molecular weight phenolics

Brief summary

Plant foods contain natural compounds called (poly)phenols, which may help lower the risk of heart and metabolic diseases. However, people differ greatly in how they absorb and process these compounds, partly because most (poly)phenols are broken down by gut bacteria in the colon. This makes it difficult to know exactly which metabolites come from the diet, and which are produced by the body. Studying people with an ileostomy provides a unique opportunity to understand how much is absorbed in the small intestine and how these compounds are transformed. This will help us better understand individual responses to dietary (poly)phenols.

Detailed description

Plant (poly)phenols are a diverse family of compounds encompassing flavonoids (e.g., flavonols, flavanones, flavones, isoflavones, anthocyanidins, flavan-3-ols) and non-flavonoids (e.g., phenolic acids, lignans, stilbenes, hydrolysable tannins), typically present in foods as glycosides. Converging evidence from cohort studies and randomised trials associates modest, long-term (poly)phenol intake with reduced risk of cardiometabolic diseases (CMD) and improved intermediate risk factors including blood pressure, endothelial -function and insulin sensitivity. Following ingestion, only a minor fraction of aglycones and small, hydrophilic forms is absorbed in the small intestine; most dietary (poly)phenols reach the colon, where gut microbiota (GM) convert them into a wide array of low-molecular weight metabolites (LMWP) that enter the circulation predominantly as phase II conjugates (glucuronides, sulfates, methylated forms). These circulating LMWP often present at higher concentrations than parent compounds and are increasingly considered the mediators of biological effects. However, bioavailability shows striking inter-individual variability (15-99% recovery as diverse metabolites), reflecting differences in absorption, distribution, metabolism, and excretion (ADME). Genetic variation may explain up to \ 50% of variability in flavonoid ADME, with remaining variability largely determined by lifestyle factors, (patho)physiology, and GM composition/function. GMdependent- transformations generate distinct metabolic phenotypes (metabotypes) characterised by the presence/absence and relative abundance of specific catabolites. Importantly, metabotypes are associated with baseline cardiometabolic risk and intervention responsiveness and can inform stratified or personalised nutrition approaches. Interpreting LMWP profiles is complicated by biochemical convergence between dietary and endogenous pathways. For example, hippuric acid - a major endpoint of many (poly)phenols - is also formed via glycine conjugation of benzoate in glycine deportation; benzoic acid itself arises from both (poly)phenol catabolism and aromatic amino acid (phenylalanine/tyrosine) metabolism. These overlaps, together with interindividual variability in GM and host genetics, underscore the need to carefully map circulating LMWP, quantify exposure, and apportion sources to understand diet-health relationships. Studying people without a colon (ileostomates) offers a powerful in vivo model to disentangle small intestinal absorption and phase II conjugation from colonic microbial metabolism. Sampling ileal effluent will allow for (i) direct assessment of parent compounds which escape from the small intestine, (ii) characterisation of early conjugated metabolites entering circulation independent of colonic metabolism, and (iii) clearer attribution of LMWP to endogenous versus dietary origins whilst accounting for inter-individual variability. In sum, while plant (poly)phenols are linked to cardiometabolic benefits, substantial heterogeneity in ADME - shaped by GM, genetics, and endogenous pathway overlap - limits understanding of their role in nutrition and health. Integrating metabotyping concepts with the ileostomy model can resolve key uncertainties in true internal exposure and source attribution of LMWP, strengthening causal inference about diet-metabolite-health pathways and will improve our understanding on the determinants of the responsiveness to (poly)phenols, being able to predict their health effects at individual level.

Interventions

DIETARY_SUPPLEMENT(Poly)phenol rich capsules

(Poly)phenol rich capsules (\~3 g)

Sponsors

University of Ulster
Lead SponsorOTHER
University of Parma
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

Single arm acute feeding study

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Currently living with an ileostomy * \> 1-year post-operative * Aged 18 - 75 years * BMI 18 - 28 kg/m2 * Males and females (not currently pregnant / lactating) * Non-smokers (including vaping) * Not taking antibiotic therapy 3 months prior to the study * No phytochemical supplement usage 2 weeks prior to study start. * Free-living (i.e. not housebound) * No participation in other biomedical studies 3 months prior.

Exclusion criteria

* Not currently living with an ileostomy * Ileostomy formed \< 1 year previously * Not aged 18 - 75 years * BMI \<18 or \>28 kg/m2 * Pregnant / lactating female * Smokers (including vaping) * Those taking antibiotic therapy 3 months prior to the study * Phytochemical supplement usage within 2 weeks of study start. * Housebound or otherwise unable to attend testing visits. * Participation in a biomedical study (3 months prior to study start).

Design outcomes

Primary

MeasureTime frameDescription
Variability of phenolic metabolites in ileal fluidFrom enrolment to the end of treatment at 1 week.The primary objective will be assessment of the variability in the ileal concentration of phenolic metabolites among individuals and the potential grouping of the individuals into metabotypes after acute (poly)phenol consumption.

Secondary

MeasureTime frameDescription
Identification and quantification of low molecular weight phenolicsFrom enrolment to end of treatment at 1 week.Identify and quantify the low molecular weight phenolics (LMWP) in biological samples (urine, ileal fluid) in a low-(poly)phenol controlled diet context, before and after the intake of (poly)phenol-rich capsules, therefore allowing for assessment of the ratio of exogenous/endogenous sources of LMWP.
Influence of macronutrients over low molecular weight phenolic productionFrom enrolment to end of treatment at 1 week.Evaluate the influence of macronutrients over LMWP production considering the subject's microbiota profiles and single nucleotide polymorphisms (SNPs).

Countries

United Kingdom

Contacts

CONTACTChris IR Gill, PhD
c.gill@ulster.ac.uk+44 28 7012 3181
CONTACTRuth Price, PhD
rk.price@ulster.ac.uk+442870123878

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 20, 2026